Tissue Regenix (GB:TRX) has released an update.
Tissue Regenix, a key player in regenerative medical devices, has granted significant stock options to its top executives following a positive 2024 trading update. CEO Daniel Lee and CFO David Cocke were awarded restricted share units (RSUs), while EMEA Business Director Kirsten Lund received Conditional Share Awards (CSAs), all contingent on performance and service conditions over three years. These grants represent a notable increase in their stakes, with Lee and Cocke now holding 0.9% and 0.7% of the company’s current issued share capital, respectively.
For further insights into GB:TRX stock, check out TipRanks’ Stock Analysis page.
